Evaluate the Safety and Effectiveness of Sodium Hyaluronate When Used for the Correction of Nasolabial Folds

Lidocaine Clinical Trial

Official title:

A Randomized, Within-subject Controlled Clinical Study to Evaluate the Safety and Effectiveness of Pain Relief of Modified Sodium Hyaluronate Gel for Injection When Used for the Correction of Moderate or Severe Nasolabial Folds

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04569045
• Other study ID #: RDCT-CNFL
• Status: Completed
• Phase: N/A
• Start date: August 20, 2020
• Est. completion date: December 10, 2021

Study information

• Verified date: February 2021
• Source: SciVision Biotech Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to evaluate the safety and effectiveness of pain relief of modified sodium hyaluronate gel for injection when used for the correction of moderate or severe nasolabial folds.

Description:

One hundred and thirty patients were enrolled and there two sides of nasolabial folds (NLF) were randomized to receive HA with lidocaine or HA. The primary outcome was immediate visual analogue scale (VAS) of pain evaluated after injection for both NLF sides. Secondary outcomes including VAS pain, wrinkle severity rating scale (WSRS), global aesthetic improvement scale (GAIS) and AE were observed at 1, 3, 6, 9, 12 follow-ups.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 130
• Est. completion date: December 10, 2021
• Est. primary completion date: December 4, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Age 18 to 65 years of male or female
• Wrinkle Severity Rating Scale (WSRS) of bilateral nasolabial folds graded 3 or 4 by blinded evaluator (moderate to severe bilateral nasolabial fold), consistent grade of bilateral nasolabial folds, and the grades approved by the physician who perform the treatment
• Agree not to undergo any other under-eye facial surgery (including nose) during the study period

Exclusion Criteria:

• Injection site with infection or other skin diseases present which may affect the evaluation
• With medical history of chromatosis, discoloration, keloid formation, hypertrophic scarring at nasolabial folds
• With permanent implants or planning to receive permanent implants during the study period at the injection sites
• Hyaluronate facial dermal implant injection or other impermanent dermal fillers injection at injection sites within the past 12 months
• With under-eye facial Botox or fat injection within the past 6 months or planning to receive under-eye facial Botox or fat injection during the study period
• With under-eye facial chemical or lasers peeling, non-invasive skin tightening, thermocool within the past 3 months or planning to receive these aesthetic procedures during the study period
• With prescription medication for nasolabial fold treatment, topical corticosteroid, skinirritating topical products or pigmentation products within the past 2 weeks or planning to take these medication or products during the study period
• With systemic immunosuppressive therapy or systemic corticosteroids within the past 2 months or planning to receive these therapies during the study period (subjects who have received inhaled/intranasal corticosteroids could be considered to include.)
• Severe liver or kidney defects (such as the value of ALT or AST over 1.5 folds of upper limit of normal value; the value of creatinine over 1.5 folds of upper limit of normal value)
• With clinical meaningful coagulation disorders, underdoing anticoagulant treatment or within the past 10 days, or taking blood circulation promotion and blood stasis removement medications
• With epilepsy or porphyria
• With congenital or idiopathic methemoglobinemia or glucose-6-phosphate dehydrogenase deficiency
• With the need to take b-blocker during the study period
• With severe atrioventricular block (type 2 second-degree AV block and third-degree AV block)
• With analgesic dependence, analgesics within the past 2 weeks or planning to receive analgesics during the study period
• With orthodontics, tooth extraction, tooth implantation (extraction or implantation of tooth anterior to the second premolar) or planning to receive these procedures during the study
• With history of hypersensitivity or allergy to lidocaine, amide anesthetics, hyaluronic acid or any component of the device; Gram-positive bacterial or Streptococcus proteins; other severe hypersensitivity history unsuitable for participating in the study
• Planning to undergo any surgery which may cause significant body weight change (such as bariatric surgery) or take any medication which may cause significant body weight change
• Pregnant, planning pregnancy or in breastfeeding females
• With syphilis or HIV infection
• Participated in clinical study of other device or drug and have not terminated within the past 30 days -Other circumstances which judged to be unsuitable for participating in the study by the investigator

Related Conditions & MeSH terms

• Dermal Filler
• Hyaluronic Acid
• Lidocaine
• Nasolabial Fold

Intervention

Device:
• HA+Lidocaine
20 mg
• HA
20 mg

Locations

Country	Name	City	State
China	Beijing	Beijing
China	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
SciVision Biotech Inc.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Immediate VAS pain evaluated after injection for both NLF sides	The VAS scale uses a 100 mm line labelled at '0' with 'no pain' and '100' with 'worst pain'.	Immediate post-injection
Secondary	VAS pain evaluated 15, 30, 45 and 60 minutes after injection for both NLF sides	The VAS scale uses a 100 mm line labelled at '0' with 'no pain' and '100' with 'worst pain'.	15, 30, 45 and 60 minutes post-injection
Secondary	On-site WSRS evaluated by site blinded-evaluator at 1, 3, 6, 9 and 12 months	Evaluators assess the wrinkle severity of nasolabial folds on site or photographically with 5 graded scale,1 to 5 was represented 'absent' to 'extreme'.	1, 3, 6, 9 and 12 months post-injection
Secondary	GAIS evaluated photographically by independent blinded-evaluator at 1, 3, 6, 9 and 12 months	Evaluators and subjects assess the improvement of correction with 5 graded scale,1 to 5 was represented 'exceptional improvement' to 'worsened'.	1, 3, 6, 9 and 12 months post-injection
Secondary	Adverse events reported from the baseline and during the study period	The safety assessment was based on reports of adverse events, defined as any unwanted events whether it was thought to be related to the study drugs or not, were recorded during each follow up and at any time the patient reported an event to the investigator during the study period.	1, 3, 6, 9 and 12 months post-injection